Brokerages Set REGENXBIO Inc. (NASDAQ:RGNX) Target Price at $33.45

REGENXBIO Inc. (NASDAQ:RGNX) has earned a consensus rating of “Moderate Buy” from the ten analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $34.70.

A number of research firms have recently issued reports on RGNX. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Tuesday, February 25th. Royal Bank of Canada reissued an “outperform” rating and set a $30.00 price target on shares of REGENXBIO in a research report on Tuesday, January 21st. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of REGENXBIO in a research report on Wednesday, January 15th. Chardan Capital reissued a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research report on Wednesday, November 20th. Finally, Raymond James initiated coverage on shares of REGENXBIO in a research report on Friday, February 7th. They set an “outperform” rating and a $27.00 price target on the stock.

Institutional Trading of REGENXBIO

Several hedge funds have recently made changes to their positions in RGNX. China Universal Asset Management Co. Ltd. lifted its position in shares of REGENXBIO by 64.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 3,720 shares in the last quarter. Harbor Capital Advisors Inc. lifted its position in shares of REGENXBIO by 48.5% during the third quarter. Harbor Capital Advisors Inc. now owns 36,082 shares of the biotechnology company’s stock worth $379,000 after purchasing an additional 11,784 shares in the last quarter. Sigma Planning Corp lifted its position in shares of REGENXBIO by 17.5% during the third quarter. Sigma Planning Corp now owns 38,210 shares of the biotechnology company’s stock worth $401,000 after purchasing an additional 5,701 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of REGENXBIO during the third quarter worth approximately $643,000. Finally, Intech Investment Management LLC purchased a new stake in shares of REGENXBIO during the third quarter worth approximately $161,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Stock Down 9.9 %

REGENXBIO stock opened at $5.92 on Tuesday. REGENXBIO has a 52-week low of $5.91 and a 52-week high of $28.80. The firm has a market capitalization of $293.31 million, a price-to-earnings ratio of -1.18 and a beta of 1.29. The company has a fifty day simple moving average of $7.57 and a 200-day simple moving average of $9.41.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.